Discovery of GLPG2737, a Potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-corrector-Reference-Cited by-同舟云学术

Discovery of GLPG2737, a Potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-corrector

Published:2024-03-25 Issue:7 Volume:67 Page:5216-5232
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Pizzonero Mathieu¹,Akkari Rhalid¹,Bock Xavier¹,Gosmini Romain¹^ORCID,De Lemos Elsa¹,Duthion Béranger¹,Newsome Gregory¹,Mai Thi-Thu-Trang¹,Roques Virginie¹,Jary Hélène¹,Lefrancois Jean-Michel¹,Cherel Laetitia¹,Quenehen Vanessa¹,Babel Marielle¹,Merayo Nuria¹,Bienvenu Natacha¹,Mammoliti Oscar²^ORCID,Coti Ghjuvanni²^ORCID,Palisse Adeline²,Cowart Marlon³,Shrestha Anurupa³,Greszler Stephen³^ORCID,Van Der Plas Steven²,Jansen Koen²,Claes Pieter²^ORCID,Jans Mia²,Gees Maarten²,Borgonovi Monica¹,De Wilde Gert²,Conrath Katja²

Affiliation:

1. Galapagos SASU, 102 Avenue Gaston Roussel, 93230 Romainville, France

2. Galapagos NV, Generaal De Wittelaan L11, A3, 2800 Mechelen, Belgium

3. AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064-1802, United States

Funder

Gal?pagos

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c01790

Reference25 articles.

1. Worldwide rates of diagnosis and effective treatment for cystic fibrosis

2. ECFSPR Annual Report 2020. Available from: https://www.ecfs.eu/projects/ecfs-patient-registry/annual-reports (accessed 14 June 2023).

3. Modulators of CFTR. Updates on clinical development and future directions

4. CFTR1 Database. Available from: http://www.genet.sickkids.on.ca/ (accessed 22 June 2023).

5. CTTR2 Database. Available from: https://cftr2.org/ (accessed 22 June 2023).